Open AccessLongitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9‐year study
Author(s) -
Stomrud Erik,
Minthon Lennart,
Zetterberg Henrik,
Blennow Kaj,
Hansson Oskar
Publication year - 2015
Publication title -
alzheimer's and dementia: diagnosis, assessment and disease monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.497
H-Index - 37
ISSN - 2352-8729
DOI - 10.1016/j.dadm.2015.09.002
Subject(s) - medicine , cerebrospinal fluid , biomarker , asymptomatic , dementia , disease , oncology , prospective cohort study , cognitive decline , clinical trial , alzheimer's disease , longitudinal study , pathology , biochemistry , chemistry
Ascertainment of the pattern and temporal change of biomarkers in preclinical (asymptomatic) sporadic Alzheimer's disease (AD) will increase knowledge about early pathogenesis and facilitate interventional therapeutic trials. Methods In this prospective longitudinal study, repeated cerebrospinal fluid (CSF) collections and cognitive evaluations were performed in cognitively healthy elderly individuals during a 9‐year period. Results Low CSF β‐amyloid (Aβ) 42 levels predicted subsequent development of clinical AD 9 years later. Noteworthy, one‐third of individuals with pathologically low baseline Aβ 42 levels remained cognitively intact during follow‐up. No further decrease in Aβ 42 was seen in those with low levels already at baseline. Discussion CSF Aβ 42 predicts sporadic AD at least 9 years before dementia onset and has plateaued already at this time. However, many individuals can harbor brain amyloid accumulation over a decade without signs of cognitive deterioration, which could implicate how CSF biomarkers are used to identify preclinical AD in future interventional therapeutic trials.